EP3316881A4 - SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT - Google Patents

SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT Download PDF

Info

Publication number
EP3316881A4
EP3316881A4 EP16898785.7A EP16898785A EP3316881A4 EP 3316881 A4 EP3316881 A4 EP 3316881A4 EP 16898785 A EP16898785 A EP 16898785A EP 3316881 A4 EP3316881 A4 EP 3316881A4
Authority
EP
European Patent Office
Prior art keywords
diagnosis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16898785.7A
Other languages
German (de)
French (fr)
Other versions
EP3316881A1 (en
Inventor
Randice Lisa Altschul
Neil David THEISE
Myron Rapkin
Rebecca O'brien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pop Test Oncology LLC
Original Assignee
Pop Test Oncology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/802,060 external-priority patent/US9314473B2/en
Application filed by Pop Test Oncology LLC filed Critical Pop Test Oncology LLC
Priority claimed from PCT/US2016/026876 external-priority patent/WO2017180086A1/en
Publication of EP3316881A1 publication Critical patent/EP3316881A1/en
Publication of EP3316881A4 publication Critical patent/EP3316881A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP16898785.7A 2015-07-17 2016-04-11 SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT Withdrawn EP3316881A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/802,060 US9314473B2 (en) 2011-02-03 2015-07-17 System and method for diagnosis and treatment
PCT/US2016/026876 WO2017180086A1 (en) 2016-04-11 2016-04-11 System and method for diagnosis and treatment

Publications (2)

Publication Number Publication Date
EP3316881A1 EP3316881A1 (en) 2018-05-09
EP3316881A4 true EP3316881A4 (en) 2019-05-29

Family

ID=61767978

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16898785.7A Withdrawn EP3316881A4 (en) 2015-07-17 2016-04-11 SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT

Country Status (1)

Country Link
EP (1) EP3316881A4 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012106514A2 (en) * 2011-02-03 2012-08-09 Pop Test Cortisol Llc System and method for diagnosis and treatment
WO2015089338A2 (en) * 2013-12-11 2015-06-18 Sloan-Kettering Institute For Cancer Research Glucocorticoid inhibitors for treatment of prostate cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012106514A2 (en) * 2011-02-03 2012-08-09 Pop Test Cortisol Llc System and method for diagnosis and treatment
WO2015089338A2 (en) * 2013-12-11 2015-06-18 Sloan-Kettering Institute For Cancer Research Glucocorticoid inhibitors for treatment of prostate cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RATHKOPF DANA E ET AL: "Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 31, no. 28, 1 October 2013 (2013-10-01), pages 3525 - 3530, XP008166079, ISSN: 0732-183X, [retrieved on 20130903], DOI: 10.1200/JCO.2013.50.1684 *
See also references of WO2017180086A1 *

Also Published As

Publication number Publication date
EP3316881A1 (en) 2018-05-09

Similar Documents

Publication Publication Date Title
IL281566A (en) Methods and systems for diagnosing and treating diseases
EP3688465A4 (en) DIAGNOSTIC TEST SYSTEM AND METHOD
IL259984A (en) System and methods for neurological monitoring and diagnostic assistance
EP2671086A4 (en) SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT
EP3313168A4 (en) SYSTEM AND METHOD FOR PRESCRIPTIVE SEED TREATMENT
EP3333660A4 (en) ANOMALY PREDICTOR DIAGNOSIS SYSTEM AND ANOMALY PREDICTOR DIAGNOSIS METHOD
PL4574996T3 (en) DETECTION AND TREATMENT OF DISEASES SHOWING HETEROGENEITY OF DISEASE CELLS AND SYSTEMS AND METHODS FOR TRANSMITTING TEST RESULTS
EP3333661A4 (en) ANOMALY PREDICTOR DIAGNOSIS SYSTEM AND ANOMALY PREDICTOR DIAGNOSIS METHOD
EP3347367A4 (en) METHOD AND SYSTEM FOR DIAGNOSIS AND THERAPY DERIVED FROM MICROBIOMA FOR BACTERIAL VAGINOSIS
PL3391041T3 (en) Automated clinical diagnostic system and method
EP2906151A4 (en) SYSTEM AND METHOD FOR CARDIAC TREATMENT
EP3306612A4 (en) METHOD, APPARATUS AND SYSTEM FOR KARAOKE PROCESSING
EP2913767A4 (en) METHOD, APPARATUS, AND SYSTEM FOR PAGE PROCESSING
EP3875207A4 (en) TREATMENT SYSTEM AND TREATMENT METHOD
EP3776448A4 (en) PASSENGER TREATMENT SYSTEM AND METHOD
EP3306606A4 (en) METHOD, APPARATUS AND SYSTEM FOR AUDIO PROCESSING
EP2822485A4 (en) SYSTEM AND METHOD FOR TREATING BONE FRACTURES
EP3383473A4 (en) SYSTEM AND METHOD FOR BLOOD TESTING
EP3463141A4 (en) UNWANTED TISSUE TREATMENT SYSTEM
EP3515031A4 (en) SYSTEM, APPARATUS AND METHOD FOR SESSION PROCESSING
EP3877037A4 (en) NEUROREGENERATION TREATMENT METHOD AND SYSTEM
EP3283648A4 (en) METHOD AND SYSTEM FOR DIAGNOSING DERIVATIVES OF MICROBIOMA AND TREATING THERAPEUTIC PROBLEMS FOR NEUROLOGICAL HEALTH PROBLEMS
EP3435616A4 (en) METHOD AND APPARATUS FOR MULTICAST DELAY DIAGNOSIS
EP3371683A4 (en) SYSTEM AND METHOD FOR DESIGN
EP3347844A4 (en) METHOD AND SYSTEM FOR DIAGNOSING DISEASE AND GENERATING TREATMENT RECOMMENDATIONS

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180116

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/00 20060101ALI20190124BHEP

Ipc: A61K 31/357 20060101AFI20190124BHEP

Ipc: A61K 45/06 20060101ALI20190124BHEP

Ipc: A61K 31/395 20060101ALI20190124BHEP

Ipc: A61P 35/00 20060101ALI20190124BHEP

Ipc: A61K 31/4439 20060101ALI20190124BHEP

Ipc: A61K 31/575 20060101ALI20190124BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20190430

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/395 20060101ALI20190424BHEP

Ipc: A61K 31/575 20060101ALI20190424BHEP

Ipc: A61K 45/06 20060101ALI20190424BHEP

Ipc: A61K 31/4439 20060101ALI20190424BHEP

Ipc: A61P 35/00 20060101ALI20190424BHEP

Ipc: A61P 31/00 20060101ALI20190424BHEP

Ipc: A61K 31/357 20060101AFI20190424BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20201002

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20241101